MA44557A1 - Vaccin contre le rotavirus sans tampon, stable en milieu acide, et d'un faible volume de dose à administrer - Google Patents

Vaccin contre le rotavirus sans tampon, stable en milieu acide, et d'un faible volume de dose à administrer

Info

Publication number
MA44557A1
MA44557A1 MA44557A MA44557A MA44557A1 MA 44557 A1 MA44557 A1 MA 44557A1 MA 44557 A MA44557 A MA 44557A MA 44557 A MA44557 A MA 44557A MA 44557 A1 MA44557 A1 MA 44557A1
Authority
MA
Morocco
Prior art keywords
vaccine
buffer
low dose
administer
dose volume
Prior art date
Application number
MA44557A
Other languages
English (en)
Other versions
MA44557B1 (fr
Inventor
Krishna Mohan Vadrevu
Sai Devarajulu Prasad
Krishna Murthy Ella
Original Assignee
Bharat Biotech Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bharat Biotech Int Ltd filed Critical Bharat Biotech Int Ltd
Publication of MA44557A1 publication Critical patent/MA44557A1/fr
Publication of MA44557B1 publication Critical patent/MA44557B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne un vaccin contre le rotavirus sans tampon, stable en milieu acide, et d'un faible volume de dose à administrer. Le vaccin est disponible sous la forme de doses d'un volume inférieur à 1 ml par dose destinées à être administrées par voie orale, et ne contient pas de tampon. Le vaccin ne nécessite pas d'administration, avant ou après l'administration par voie orale du vaccin au patient, d'anti-acide qui viserait à neutraliser l'acidité gastrique. Le vaccin montre une diminution de la ch
MA44557A 2016-06-16 2017-06-12 Vaccin contre le rotavirus sans tampon, stable en milieu acide, et d'un faible volume de dose à administrer MA44557B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201641020675 2016-06-16
PCT/IN2017/050237 WO2017216808A1 (fr) 2016-06-16 2017-06-13 Vaccin contre le rotavirus sans tampon, stable en milieu acide, et d'un faible volume de dose à administrer

Publications (2)

Publication Number Publication Date
MA44557A1 true MA44557A1 (fr) 2020-01-31
MA44557B1 MA44557B1 (fr) 2021-11-30

Family

ID=60664101

Family Applications (1)

Application Number Title Priority Date Filing Date
MA44557A MA44557B1 (fr) 2016-06-16 2017-06-12 Vaccin contre le rotavirus sans tampon, stable en milieu acide, et d'un faible volume de dose à administrer

Country Status (21)

Country Link
US (1) US11351245B2 (fr)
EP (1) EP3471768B1 (fr)
JP (1) JP7108549B2 (fr)
KR (3) KR102792978B1 (fr)
CN (1) CN109562159B (fr)
AU (1) AU2017285408B2 (fr)
CA (1) CA3027703A1 (fr)
CO (1) CO2019000078A2 (fr)
EA (1) EA201990027A1 (fr)
GB (1) GB2566244B (fr)
IL (1) IL263740B2 (fr)
JO (1) JOP20180124B1 (fr)
MA (1) MA44557B1 (fr)
MX (1) MX2018015469A (fr)
MY (1) MY198419A (fr)
PH (1) PH12018502650B1 (fr)
SG (2) SG10202012281TA (fr)
TN (1) TN2018000436A1 (fr)
UA (1) UA124430C2 (fr)
WO (1) WO2017216808A1 (fr)
ZA (1) ZA201900176B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220370595A1 (en) * 2016-06-16 2022-11-24 Bharat Biotech International Limited Buffer Free, Acid Stable Low Dose Volume Rotavirus Vaccine

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6616931B1 (en) 1996-09-26 2003-09-09 Merck & Co., Inc. Rotavirus vaccine formulations
WO1998013065A1 (fr) 1996-09-26 1998-04-02 Merck & Co., Inc. Formulations de vaccins a rotavirus
US6403098B1 (en) 1996-09-26 2002-06-11 Merck & Co., Inc. Rotavirus vaccine formulations
KR19990072201A (ko) * 1996-10-18 1999-09-27 무타이 마사히꼬 로타바이러스 항원, 로타바이러스 감염증에 대한백신 및 진단제와 항원 제조방법
BRPI9912485B8 (pt) * 1998-07-28 2021-05-25 The Government Of The Us Secretary Department Of Health And Human Services composição imunogênica multivalente
TR200200420T2 (tr) 1999-08-17 2002-05-21 Smithkline Beecham Biologicals S.A. Aşı
JP2005038411A (ja) 2003-06-30 2005-02-10 Sony Corp 機器認証情報組込システム、端末機器、機器認証情報処理方法、機器認証情報処理プログラム、提供サーバ、機器認証情報提供方法、機器認証情報提供プログラム、及び記憶媒体
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
GB0516944D0 (en) * 2005-08-17 2005-09-28 Glaxosmithkline Biolog Sa Vaccine
MX2008014391A (es) 2006-05-12 2009-03-06 Bharat Biotech Int Ltd Una composicion util como vacuna.
CN101638638A (zh) * 2008-07-29 2010-02-03 辽宁依生生物制药有限公司 人猪重配轮状病毒
CN102470170B (zh) 2009-07-13 2015-03-18 巴拉特生物技术国际有限公司 用作轮状病毒疫苗的组合物及其方法
BR112013027457A2 (pt) * 2011-04-28 2019-09-24 Int Medica Foundation preparação de vacina, e, métodos de fabricar uma preparação de vacina, e de vacinar um mamífero
CN110227152A (zh) 2012-04-23 2019-09-13 巴拉特生物技术国际有限公司 轮状病毒疫苗组合物及其制备方法

Also Published As

Publication number Publication date
JOP20180124B1 (ar) 2024-04-18
KR20220063302A (ko) 2022-05-17
ZA201900176B (en) 2019-09-25
CO2019000078A2 (es) 2019-01-18
KR102792978B1 (ko) 2025-04-07
KR20190020046A (ko) 2019-02-27
CN109562159A (zh) 2019-04-02
MX2018015469A (es) 2019-04-24
IL263740A (en) 2019-01-31
JOP20180124A1 (ar) 2019-01-30
EA201990027A1 (ru) 2019-07-31
SG11201811188TA (en) 2019-01-30
MY198419A (en) 2023-08-29
IL263740B2 (en) 2024-01-01
PH12018502650B1 (en) 2023-03-24
WO2017216808A1 (fr) 2017-12-21
CA3027703A1 (fr) 2017-12-21
AU2017285408A1 (en) 2019-01-31
JP7108549B2 (ja) 2022-07-28
US11351245B2 (en) 2022-06-07
GB201900562D0 (en) 2019-03-06
KR20230125863A (ko) 2023-08-29
EP3471768A1 (fr) 2019-04-24
SG10202012281TA (en) 2021-01-28
US20190142932A1 (en) 2019-05-16
MA44557B1 (fr) 2021-11-30
EP3471768B1 (fr) 2025-05-07
EP3471768A4 (fr) 2020-03-04
JP2019518056A (ja) 2019-06-27
AU2017285408B2 (en) 2024-05-02
IL263740B1 (en) 2023-09-01
PH12018502650A1 (en) 2019-10-07
CN109562159B (zh) 2022-10-28
GB2566244B (en) 2021-10-13
GB2566244A (en) 2019-03-06
UA124430C2 (uk) 2021-09-15
TN2018000436A1 (en) 2020-06-15
BR112018076094A2 (pt) 2019-03-26

Similar Documents

Publication Publication Date Title
CL2019003091A1 (es) Terapia de combinación.
NZ780890A (en) Pharmaceutical compositions comprising meloxicam
EA202090573A1 (ru) Составы нирапариба
EA201790568A1 (ru) Применение двойного агониста рецепторов glp-1/глюкагона пролонгированного действия для лечения неалкогольной жировой болезни печени
UA124347C2 (uk) Циклічна динуклеотидна сполука
BR112018068748A2 (pt) composto, composição farmacêutica e de vacina, métodos para indução ou promoção de uma resposta imunológica, para tratamento de câncer, de doenças infecciosas, de distúrbios imunológicos e de doenças imunológicas e para tratamento ou prevenção de uma doença, e, uso de um composto
CA3030422C (fr) Excipients stabilisants pour formulations de proteines therapeutiques
EA201792592A1 (ru) Фармацевтические препараты, содержащие тенофовир и эмтрицитабин
RU2017132877A (ru) Комбинация антагониста pd-1 и эрибулина для лечения рака
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
EA201792591A1 (ru) Фармацевтические препараты
CL2019003533A1 (es) Uso de vibegron para tratar vejiga sobreactiva.
EA202090542A1 (ru) Высококонцентрированные лекарственные формы придопидина
IT201800001301A1 (it) Formulazioni in gel per la somministrazione orale di farmaci, in particolare nei pazienti disfagici
EA201792144A1 (ru) Стабильный препарат для парентерального введения тапентадола
PH12019500516A1 (en) Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
MA44557A1 (fr) Vaccin contre le rotavirus sans tampon, stable en milieu acide, et d'un faible volume de dose à administrer
CO2025007025A2 (es) Formulaciones orales compactables de ibutamoren
MX2017015202A (es) Formulaciones liquidas de celecoxib para administracion oral.
MX2020000009A (es) Nuevas formulaciones en capsulas de gelatina blandas de secnidazol y sus usos.
PH12014501601A1 (en) Artemisinin-based combination therapy for treating viral mediated disease
WO2014193269A3 (fr) Médicament à base de diindolylméthane et son utilisation pour traiter la grippe et les infections virales respiratoires
EA201900586A1 (ru) Комбинированный лекарственный препарат для терапии вирусных инфекций
MX393290B (es) Composicion para el tratamiento de la osteoartritis